Abstract
Survivin is a new member of the inhibitor of apoptosis protein (IAP) family that is implicated in the control of cell proliferation and the regulation of cell life span. This protein is selectively expressed in most human carcinomas but not in normal adult tissues. To down-regulate a human survivin expression as a strategy for cancer gene therapy, we designed two hammerhead ribozymes (RZ-1, RZ-2) targeting human survivin mRNA. RZ-1 and RZ-2 efficiently cleaved the human survivin mRNA at nucleotide positions +279 and +289, which was identified by in vitro cleavage assay using in vitro transcribed ribozymes and truncated survivin mRNA substrate. To investigate the function of the ribozymes in cells, the sequences of the ribozymes were cloned into replication-deficient adenoviral vector and transferred to breast cancer cell, MCF-7. The infection with adenovirus encoding the ribozymes resulted in a significant reduction of survivin mRNA (74% and 73%, respectively) and protein. As revealed by nuclear condensation/ fragmentation and flow cytometry analysis, inhibition of survivin gene by ribozymes increased apoptosis and sensitivity induced by etoposide or serum starvation. Our results suggest that the designed hammerhead ribozymes against survivin mRNA are good candidates for feasible gene therapy in the treatment of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nagata S . Apoptosis by death factor. Cell. 1997;88:355–365.
Vaux DL, Haecker G, Strasser A . An evolutionary perspective on apoptosis. Cell. 1994;76:777–779.
Thompson CB . Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462.
Adams JM, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326.
Deveraux QL, Reed JC . IAP family proteins — suppressors of apoptosis. Genes Dev. 1999;13:239–252.
Lacasse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–3259.
Birnbaum MJ, Clem RJ, Miller LK . An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol. 1994;68:2521–2528.
Crook NE, Clem RJ, Miller LK . An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol. 1993;67:2168–2174.
Ambrosini G, Adida C, Altieri DC . A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921.
Chiodino C, Cesinaro AM, Ottani D, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol. 1999;113:415–418.
Konno R, Yamakawa H, Utsunomiya H, et al. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod. 2000;6:529–534.
Jiang X, Wilford C, Duensing S, et al. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J Cell Biochem. 2001;83:342–354.
Monzo M, Rosell R, Felip E, et al. Novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1997;17:2100–2104.
Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127–134.
Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin shorter survival rates in colorectal cancers. Cancer Res. 1998;58:5071–5074.
Lu CD, Altieri DC, Tanigawa N . Expression of novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808–1812.
Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–95.
Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271–278.
Swana HS, Grossman D, Anthony JN, et al. Tumor content of the anti-apoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999;341:452–453.
Saitoh Y, Yaginuma Y, Ishikawa M . Analysis of Bcl-2, Bax and survivin genes in uterine cancer. Int J Oncol. 1999;15:137–141.
Yoshida H, Ishiko O, Sumi T, et al. Survivin, Bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol. 2001;19:537–542.
Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925.
Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukemia. Br J Haematol. 2000;111:196–203.
Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukemia: survivin is important determinant for prognosis. Br J Haematol. 2001;114:63–69.
Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–883.
Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–623.
Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–1081.
Grossman D, McNiff JM, Li F, et al. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest. 1999;79:1121–1126.
Sullivan S . Development of ribozymes for gene therapy. J Invest Dermatol. 1994;103:85S–95S.
Haseloff J, Gerlach WL . Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 1988;334:585–591.
Stein CA . Does antisense exists? Nat Med. 1995;1:1119–1121.
Wagner RW . Toward a broad-based antisense technology. Antisense Res Dev. 1995;5:113–114.
Yokoyama Y, Morishita S, Takahashi Y, et al. Modulation of c-fos proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme. Br J Cancer. 1997;76:977–982.
Kashani-Sabet M, Funato T, Tone T, et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev. 1992;2:3–15.
Lavrovsky Y, Tyagi RK, Chen S, et al. Ribozyme-mediated cleavage of the estrogen receptor messenger RNA and inhibition of receptor function in target cells. Mol Endocrinol. 1999;13:925–934.
Chen S, Song CS, Lavrovsky Y, et al. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol. 1998;12:1558–1566.
Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1999;1:461–466.
Chen J, Wu W, Tahir SK, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia. 2000;2:235–241.
Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805–2809.
Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–11182.
Kanwar JR, Shen WP, Kanwar RK, et al. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 2001;93:1541–1552.
Kallio MJ, Nieminen M, Eriksson JE . Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J. 2001;15:2721–2723.
Shankar SL, Mani S, O'Guin KN, et al. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem. 2001;79:426–436.
Grossman D, Kim PJ, Schechner JS, et al. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci. 2001;98:635–640.
Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108:981–990.
Guo S, Kemphues KJ . par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 1995;81:611–620.
Hendrix C, Anne J, Joris B, et al. Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA. Biochem J. 1996;314:655–661.
Fedor MJ, Uhlenbeck OC . Substrate sequence effects on “hammerhead” RNA catalytic efficiency. Proc Natl Acad Sci. 1990;87:1668–1672.
Herschlag D, Cech TR . Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme: 2. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. Biochemistry. 1990;29:10172–10180.
Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097–6102.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, K., Lee, T. & Jung, M. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 10, 87–95 (2003). https://doi.org/10.1038/sj.cgt.7700531
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700531
Keywords
This article is cited by
-
Antiproliferative and apoptotic effects of proteins from black seeds (Nigella sativa) on human breast MCF-7 cancer cell line
BMC Complementary Medicine and Therapies (2020)
-
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Journal of Experimental & Clinical Cancer Research (2019)
-
Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma
Cellular & Molecular Biology Letters (2017)
-
Survivin: a unique target for tumor therapy
Cancer Cell International (2016)
-
Enhanced survivin siRNA delivery using cationic liposome incorporating fatty acid-modified polyethylenimine
Chemical Research in Chinese Universities (2015)